Cite
HARVARD Citation
Jackson, C. et al. (n.d.). IMMU-18. IMMUNOGENOMIC RESPONDER PHENOTYPE FROM A PHASE I TRIAL OF ANTI-LAG3 OR ANTI-CD137 ALONE AND IN COMBINATION WITH ANTI-PD-1 IN PATIENTS WITH RECURRENT GBM. Neuro-oncology. pp. vi122-vi123. [Online].